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Summary
Background Children with complicated severe acute malnutrition (SAM) have a greatly increased risk of mortality 
from infections while in hospital and after discharge. In HIV-infected children, mortality and admission to hospital 
are prevented by daily co-trimoxazole prophylaxis, despite locally reported bacterial resistance to co-trimoxazole. We 
aimed to assess the eﬃ  cacy of daily co-trimoxazole prophylaxis on survival in children without HIV being treated for 
complicated SAM.
Methods We did a multicentre, double-blind, randomised, placebo-controlled study in four hospitals in Kenya (two rural 
hospitals in Kiliﬁ  and Malindi, and two urban hospitals in Mombasa and Nairobi) with children aged 60 days to 59 months 
without HIV admitted to hospital and diagnosed with SAM. We randomly assigned eligible participants (1:1) to 6 months 
of either daily oral co-trimoxazole prophylaxis (given as water-dispersible tablets; 120 mg per day for age <6 months, 
240 mg per day for age 6 months to 5 years) or matching placebo. Assignment was done with computer-generated 
randomisation in permuted blocks of 20, stratiﬁ ed by centre and age younger or older than 6 months. Treatment 
allocation was concealed in opaque, sealed envelopes and patients, their families, and all trial staﬀ  were masked to 
treatment assignment. Children were given recommended medical care and feeding, and followed up for 12 months. 
The primary endpoint was mortality, assessed each month for the ﬁ rst 6 months, then every 2 months for the second 
6 months. Secondary endpoints were nutritional recovery, readmission to hospital, and illness episodes treated as an 
outpatient. Analysis was by intention to treat. This trial was registered at ClinicalTrials.gov, number NCT00934492.
Findings Between Nov 20, 2009, and March 14, 2013, we recruited and assigned 1778 eligible children to treatment 
(887 to co-trimoxazole prophylaxis and 891 to placebo). Median age was 11 months (IQR 7–16 months), 306 (17%) were 
younger than 6 months, 300 (17%) had oedematous malnutrition (kwashiorkor), and 1221 (69%) were stunted (length-
for-age Z score <–2). During 1527 child-years of observation, 122 (14%) of 887 children in the co-trimoxazole group 
died, compared with 135 (15%) of 891 in the placebo group (unadjusted hazard ratio [HR] 0·90, 95% CI 0·71–1·16, 
p=0·429; 16·0 vs 17·7 events per 100 child-years observed (CYO); diﬀ erence –1·7 events per 100 CYO, 95% CI 
–5·8 to 2·4]). In the ﬁ rst 6 months of the study (while participants received study medication), 63 suspected grade 3 or 
4 associated adverse events were recorded among 57 (3%) children; 31 (2%) in the co-trimoxazole group and 32 (2%) in 
the placebo group (incidence rate ratio 0·98, 95% CI 0·58–1·65). The most common adverse events of these grades 
were urticarial rash (grade 3, equally common in both groups), neutropenia (grade 4, more common in the co-
trimoxazole group), and anaemia (both grades equally common in both groups). One child in the placebo group had 
fatal toxic epidermal necrolysis with concurrent Pseudomonas aeruginosa bacteraemia.
Interpretation Daily co-trimoxazole prophylaxis did not reduce mortality in children with complicated SAM without 
HIV. Other strategies need to be tested in clinical trials to reduce deaths in this population.
Funding Wellcome Trust, UK
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Introduction
Severe acute malnutrition (SAM) contributes to 1 million 
childhood deaths annually worldwide and its treatment is 
a key target for reducing childhood mortality.1 Infectious 
disease is thought to be the main mediator of mortality in 
children with SAM. A short course of oral antibiotics 
given to children with uncomplicated SAM treated as 
outpatients reduced mortality and treatment failure in 
Malawi.2 However, a short course of antibiotics had no 
eﬀ ect on these outcomes in Niger,3 although it did 
markedly reduce admission to hospital and improve early 
weight gain.
Children with SAM who have signs of infection or 
present with one or more Integrated Management of 
Childhood Illness danger signs,4 or do not pass an 
appetite test are classiﬁ ed as having complicated SAM, 
and WHO recommends that they should be initially 
treated in hospital—empirical antibiotics, treatment of 
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speciﬁ c medical conditions, and specialised therapeutic 
feeding are given.5 Once com plications have resolved and 
appetite returns, children continue therapeutic feeding 
as outpatients.
Complicated SAM is typically associated with a high 
inpatient mortality.6,7 However, even after provision of 
recommended treatment, apparent stabilisation, and 
discharge from hospital, children with SAM still retain a 
markedly increased risk of death. In Malawi, despite the 
provision of recommended medical and nutritional 
therapy, 17% of children with SAM (and without HIV) 
died within 1 year.8 In Bangladesh, among children with 
SAM and pneumonia, 9% died in hospital and a further 
9% died within 3 months after discharge from hospital.9 
Increased mortality after hospital discharge also occurs 
outside the context of SAM and is a generally recognised 
occurrence that might exceed inpatient mortality in 
resource-poor settings.10 In rural Kenya, children admitted 
to hospital had 7·7 times greater mortality in the year after 
discharge than community peers who were not admitted.11
Among children who are susceptible to infection 
because of HIV, daily co-trimoxazole prophylaxis reduced 
all-cause mortality and hospital admissions in two 
studies,12,13 despite high levels of antimicrobial resistance 
being identiﬁ ed in vitro among invasive isolates at the 
study sites. Co-trimoxazole protected children with HIV 
against malaria, pneumonia, and sepsis.14 In other 
contexts, co-trimoxazole prevented recurrent urinary 
tract infections,15 pneumonia in children with measles,16 
and infections in children with speciﬁ c immune 
deﬁ ciencies.17 Co-trimoxazole is inexpensive, widely 
available, and has a known safety proﬁ le.14
Findings from a systematic review have shown beneﬁ cial 
eﬀ ects of antimicrobials in children, including co-
trimoxazole, on linear and ponderal growth, possibly by 
reducing nutrient diversion from subclinical infections 
and inﬂ ammation, and preventing or treating overt 
infections.18 Antibiotics are also widely used in animal 
husbandry to promote growth. However, important 
potential harms might occur from the long-term use of 
antibiotics, including toxicity and exacerbation of 
antimicrobial resistance. Hence, for their use to be 
justiﬁ ed, major potential beneﬁ ts such as a reduction in 
mortality in high-risk groups of children should be 
targeted.19
We therefore tested our hypothesis that daily co-
trimoxazole prophylaxis would reduce mortality and 
morbidity, and improve nutritional recovery, in children 
without HIV being treated for complicated SAM.
Methods
Study design and participants
We did a two-arm, multicentre, double-blind, random-
ised, placebo-controlled trial in four hospitals in Kenya 
(two rural hospitals in Kiliﬁ , one urban hospital in 
Mombasa, and one in Nairobi). The study protocol is 
available in the supplement to this Article. All the study 
hospitals provided inpatient care for SAM, and outpatient 
therapeutic and supplementary feeding clinics supported 
by UNICEF or Concern Worldwide. In Kenya, 
Haemophilus inﬂ uenzae type b conjugate vaccine was 
introduced in 2001 and pneumococcal conjugate vaccine 
(PCV, 10-valent) was introduced during this trial in 
March, 2011.
Research in context
Evidence before this study
Children who are admitted to hospital with complicated severe 
acute malnutrition (SAM) are at greatly increased risk of 
mortality from common infections, including for a long period 
after discharge. Results from several randomised clinical trials in 
Africa have shown that daily co-trimoxazole reduces long-term 
all-cause mortality and readmissions to hospital among children 
who are susceptible to serious infections because of HIV. There is 
also evidence that antimicrobials improve growth. We aimed to 
investigate the eﬃ  cacy of co-trimoxazole prophylaxis in children 
without HIV being treated for complicated SAM. We searched 
PubMed for randomised trials without date or language 
restrictions using the MeSH terms “child”, “malnutrition”, 
“mortality”, “clinical trials as topic”, “anti-infective agents”, or 
“anti-bacterial agents”. We identiﬁ ed two clinical trials of 
short-course antibiotic treatment in children with 
uncomplicated SAM treated as outpatients, but no previous 
clinical trials of longer-term antimicrobial prophylaxis to prevent 
mortality in children with complicated SAM after stabilisation. 
Generally, adequate evidence for the eﬀ ectiveness of most 
interventions in children with SAM was absent or inconclusive.
Added value of this study
In our study, daily co-trimoxazole prophylaxis was well 
tolerated, but not eﬀ ective at preventing mortality or 
morbidity, or improving nutritional recovery, in children aged 
60 days to 59 months without HIV being treated for 
complicated SAM. However, some infections were prevented. 
Infants with complicated SAM had an especially high 
mortality during 1 year of follow-up, despite medical and 
nutritional care. Our results were diﬀ erent to those from trials 
of children with HIV, but similar to trials with children 
exposed to HIV but not infected. This outcome suggests that 
the interactions between antimicrobial prophylaxis, 
infections, and mortality depend on the speciﬁ c 
immunopathology.
Implications of all the available evidence
 SAM without HIV infection is not an indication for daily 
co-trimoxazole prophylaxis. To reduce mortality in children 
with complicated SAM will require a greater understanding of 
the condition and testing of other strategies in clinical trials.
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Children were eligible for inclusion if they were aged 
between 60 days and 59 months old, and had a diagnosis 
of SAM on the basis of mid-upper-arm circumference 
(MUAC) measurements (<11·5 cm for children aged 
≥6 months and <11·0 cm for infants aged 2–5 months) or 
presence of kwashiorkor (oedematous malnutrition); had 
a negative HIV rapid-antibody test; and had completed 
the stabilisation phase of treatment as deﬁ ned in WHO 
guidelines (appendix). All children admitted to the study 
hospitals were screened for eligibility by MUAC and 
examination for kwashiorkor. MUAC was chosen as the 
primary anthropometric criterion because of its high 
predictive value for mortality.4 Exclusion criteria were a 
known allergy to co-trimoxazole; if co-trimoxazole was 
speciﬁ cally contraindicated; serious comorbidity likely to 
be associated with mortality unrelated to infection such 
as severe heart disease or malignancy; and residence 
outside the attending hospital’s catchment area.
Children were enrolled after their parent or guardian 
provided written, informed consent and after medical 
and nutritional stabilisation—ie, in the rehabilitation 
phase of SAM treatment deﬁ ned by WHO guidelines5 
(additional details in the appendix). During the trial, 
enrolment was suspended during three long-term health-
worker strikes and during several periods of political 
unrest. The Oxford Tropical Research Ethics Committee 
(Oxford University, Oxford, UK), the Ethical Review 
Committee (Kenya Medical Research Institute, Nairobi, 
Kenya), and the Expert Committee on Clinical Trials at 
the Pharmacy and Poisons Board (Nairobi, Kenya) 
reviewed and approved the protocol. Eligibility criteria, 
consent, serious adverse events, and study endpoints 
were veriﬁ ed against source documents for all 
participants by visiting monitors.
Randomisation and masking
We randomly assigned eligible participants (1:1) to 
6 months of either daily oral co-trimoxazole prophy-
laxis (given as paediatric water-dispersible tablets; 
120 mg per day for age <6 months, 240 mg per day for age 
6 months to 5 years) or matching placebo. The assignment 
was undertaken by the trial statistician (GF) with 
computer-generated randomisation of study numbers in 
permuted blocks of 20, stratiﬁ ed according to clinical 
centre and age older or younger than 6 months. Allocation 
was concealed in opaque sealed envelopes that were 
externally labelled with study numbers and used 
sequentially at each site. Treatment packs were likewise 
prelabelled with the study numbers according to the 
randomisation schedule. All patients, their families, and 
trial staﬀ  were masked to the treatment assignment. 
When twins or siblings were both enrolled, the ﬁ rst child 
was enrolled normally, then the second child was allocated 
by a trial statistician (GF) to the same arm by providing 
investigators with the next matching study number. 
Active and placebo blister-packed water-dispersible tablets 
were identical in appearance and dissolution.
The dose regimen of co-trimoxazole was that 
recommended by WHO for HIV care.20 This dose was 
used for children aged more than 6 months in the CHAP 
and ARROW trials12,13 among children with HIV, in which 
eﬃ  cacy against mortality and admission to hospital was 
shown (details of the resultant dosing in mg/kg are in 
the appendix). Active and placebo investigational 
products were tested for dissolution, and drug content at 
the National Quality Control Laboratory (Nairobi, Kenya) 
before the study began, and again during the last year of 
enrolment.
Procedures
Baseline data on health, anthropometry, and socio-
economic status of probable prognostic importance were 
obtained by the study teams at each site. Children 
received standard care for SAM and other medical 
conditions according to WHO guidelines (2005) for 
complicated SAM.5 This care included the following 
empirical intravenous antibiotics: gentamicin (7·5 mg/kg 
intramuscular or intravenously) once per day for 7 days 
plus either benzyl penicillin (50 000 U/kg intramuscular 
or intravenously every 6 h) or ampicillin (50 mg/kg 
intramuscular or intravenously once per 6 h) for 2–7 days, 
changed to oral amoxicillin (25–40 mg/kg once per 8 h 
for up to 5 days) once medically stable. Therapeutic 
feeding was with lower protein and energy F75 milk 
during stabilisation and higher protein and energy F100 
milk during the transition and rehabilitation phases,5 
then ready-to-use therapeutic foods for children aged 
6 months or more; and expressed breastmilk or dilute 
F100 for infants aged less than 6 months; advice on 
breastfeeding and complementary feeding was given.
While the children were in hospital, their parents or 
guardians administered the trial drug, supervised by the 
study team. The decision to discharge children from 
hospital was made by the clinical team and was not 
inﬂ uenced by study procedures. At discharge, the study 
team ensured enrolment in a community-based, 
therapeutic-feeding programme, either at the hospital 
site or nearer to their home. A study ﬁ eldworker 
accompanied the family to their home at discharge to 
record an accurate route description, plot the household 
location using a handheld global positioning system, 
complete a home questionnaire, and obtain mobile-
telephone numbers for the family members.
Scheduled follow-up after enrolment was once per month 
up to 6 months, then once every 2 months from 
6 to 12 months (without study medication). We reimbursed 
fares to attend follow-up visits. Defaulters were traced by 
mobile phone or by home visit by ﬁ eldworkers. At each 
follow-up visit, anthropometric tests were done and 
remaining study drugs and empty blister packs were 
counted to assess adherence. A full blood count was done 
at enrolment, 2, 6, and 12 months. Besides regular follow-
up, the study provided a telephone hotline, a free walk-in 
clinic, and met costs of readmission to hospital.
See Online for appendix
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In the event of readmission to a study hospital, a 
standard admission clerking was undertaken and we did 
a blood culture, urine multiparameter dipstick and 
malaria rapid diagnostic test, or made up a blood slide. 
Urine was cultured when a clean sample was obtained 
and the dipstick indicated nitrites or leucocytes. For 
outpatient visits, tests were done as clinically indicated 
(laboratory methods are described in the appendix).
Outcomes
The primary outcome was mortality during the 365 days 
of the study period. Deaths in hospital were documented 
by study clinicians, including the ﬁ nal diagnoses. For 
deaths outside the study hospital, we obtained a copy of 
the death or burial certiﬁ cate from the family or village 
chief, examined copies of hospital or clinic records and, 
after a culturally appropriate period, a verbal autopsy was 
done. An endpoint review committee not directly 
involved in trial participant care (KDJJ and NM) reviewed 
all available information including medical and 
laboratory records and verbal autopsies for all deaths to 
assign causes while masked to treatment allocation.
Secondary outcomes were the frequency of non-fatal 
illness episodes resulting in readmission to hospital or 
outpatient attendance; the clinical syndromes associated 
with death or illness; pathogens detected from blood 
culture, urine culture, and malaria testing; suspected 
toxic eﬀ ects during the period that investigational 
products were received; and changes in MUAC, weight-
for-height, weight-for-length, weight-for-age, height-for-
age, length-for-age, head circumference-for-age, and 
haematological indices.
Statistical analysis
On the basis of data from a previous study of post-
discharge mortality at one of the trial sites,11 we initially 
calculated that 800 children in each arm were needed to 
give power of more than 90% to detect a 33% reduction 
in mortality at 12 months from a baseline rate of 18 deaths 
per 100 child-years, at a two-sided α-level of 0·05 
assuming 15% loss to follow-up. In April, 2011, the 
protocol was amended with respect to MUAC eligibility 
criteria to align with revised national protocols based on 
WHO guidelines and to simplify enrolment of infants 
younger than 6 months. We thus recalculated the 
necessary sample size to be 925 per arm on the basis of 
an expected reduction in the placebo arm event rate to 
15 deaths per 100 child-years, because of the more 
inclusive MUAC criteria. In September, 2013, after an 
independent statistical review by Sarah Walker (Medical 
Research Council Clinical Trials Unit, London, UK) of 
the rate of events in the placebo group and actual loss to 
follow-up (5%), a decision was made to discontinue 
enrolment when at least 875 children per arm had been 
included, maintaining the original power and eﬀ ect size.
A statistical analysis plan was reviewed and agreed by 
an independent Data and Safety Monitoring Committee 
(DSMC) and independent Trial Steering Committee 
(TSC) before unmasking the trial database. The DSMC 
oversaw the trial and reported to the TSC.
We did the analyses on an intention-to-treat basis and 
all statistical tests were two-sided. For the primary 
endpoint, we compared the two treatment allocation 
groups with respect to the primary endpoint using 
Kaplan-Meier plots and unadjusted proportional hazards 
models. We did prespeciﬁ ed subgroup analyses to assess 
38 989 paediatric admissions
29 525 children aged 2–59 months
5120 (17%) with severe acute 
malnutrition 
24 405 ineligible (without severe acute 
malnutrition)
2681 ineligible
877 positive HIV antibody test
141 HIV exposed, taking 
co trimoxazole 
376 HIV test refused or 
unavailable
630 not locally resident
339 other severe conditions*
309 died before stabilisation
9 hypersensitivity or 
contraindication
893 assigned to placebo
2 ineligible (1 had not 
completed stabilisation 
phase, 1 was HIV positive)
891 included in intention-to-treat 
analysis
First 6 months:
105 died
12 lost to follow-up
16 voluntary withdrawal
758 completed 6-month follow-up
711 completed 12-month follow-up
Second 6 months:
30 died
15 lost to follow-up
2 voluntary withdrawal
2439 children eligible
658 not enrolled
162 absconded or discharged 
before enrolment
496 unwilling to participate1781 enrolled and randomised
888 assigned to co-trimoxazole
1 ineligible (HIV positive)
887 included in intention-to-treat 
analysis
First 6 months:
105 died
15 lost to follow-up
15 voluntary withdrawal
752 completed 6-month follow-up
Second 6 months:
17 died
14 lost to follow-up
3 voluntary withdrawal
718 completed 12-month follow-up
Figure 1: Trial proﬁ le
*Includes severe congenital or acquired heart disease, malignancy, or probably terminal illness.
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heterogeneity of eﬀ ect by age, kwashiorkor, and study 
period: the ﬁ rst 6 months (receiving study medication) 
and the second 6 months (oﬀ  study medication). We 
assessed evidence of heterogeneity in the eﬀ ect of 
randomised allocation across subgroups by comparing 
models including interaction terms, with models with 
main eﬀ ects only, using log-likelihood ratio tests.
Morbidity events between randomised groups were 
compared by their incidence rate ratio (events per 
100 child-years observed). We compared the distributions 
of continuous variables using student’s t test, or Wilcoxon’s 
rank-sum test if the variables were skewed. We compared 
categorical variables between randomised groups using χ² 
tests. Trends in proportions across ordered groups were 
assessed by a non-parametric test for trend.
We did two post-hoc exploratory analyses to interpret 
the main ﬁ ndings. The ﬁ rst investigated eﬀ ect modi-
ﬁ cation by participants’ receipt of conjugate pneumo -
coccal vaccine, which was introduced during the trial. 
The second investigated eﬀ ect modiﬁ cation by the 
presence or absence of the most common clinical 
syndromes—severe pneumonia and diarrhoea—at initial 
presentation. We did both analyses with log-likelihood 
ratio tests, as described earlier. This trial was registered 
at ClinicalTrials.gov, number NCT00934492.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Nov 20, 2009, and March 14, 2013, from 
2439 eligible children we recruited 1781 (ﬁ gure 1, 
appendix). Three participants were withdrawn by the 
study team as ineligible soon after enrolment, without 
knowledge of their allocation. Thus, we analysed data 
from 1778 children: 887 assigned to co-trimoxazole 
prophylaxis and 891 to placebo.
The 1778 children had a median age of 11 months (IQR 
7–16), 306 (17%) were younger than 6 months, 300 (17%) 
had kwashiorkor (appendix). Of the 1478 children without 
kwashiorkor, 1281 (87%) and 908 (61%) had weight-for-
height Z scores of less than –2 and less than –3, 
respectively. Of 1778 children, 1221 (69%) and 784 (44%) 
had length-for-age Z scores of less than –2 and –3, 
respectively, and 230 children (13%) had clinical signs of 
rickets. At baseline, 1092 (61%) participants were 
breastfed, including 256 (84%) of the 306 infants younger 
than 6 months. Baseline characteristics were similar 
between the two groups (table 1).
56 (3%) of 1778 children were lost to follow-up after a 
median of 186 days (IQR 66–303) and 36 (2%) voluntarily 
withdrew from further follow-up after a median of 
73 days  (IQR 47–126). We noted no diﬀ erences between 
the groups in losses to follow-up or withdrawal (p=0·833). 
The total follow-up time was 763·3 child-years of 
observation (CYO) in the co-trimoxazole group and 
763·3 CYO in the placebo group.
Adherence, measured on the basis of empty blister-
pack counts, was a median of 95·5% (IQR 82·3–98·4%) 
in the co-trimoxazole group and 95·4% (74·2–98·8%) in 
the placebo group (p=0·666; appendix). Three children 
had a positive HIV-antibody test when readmitted to 
hospital, despite a negative test at enrolment (two 
assigned to placebo and one to co-trimoxazole). They 
were given open-label co-trimoxazole, maintained in 
follow-up, and included in the analysis on the intention-
to-treat principle.
During 1527 CYO, 257 deaths occurred (14%, 
16·8 per 100 CYO; 95% CI 14·9–19·0), 60 (23%) of which 
Placebo N=891 Co-trimoxazole 
N=887
Age (months) 10·8 (6·9–16·7) 11·2 (7·2–16·7)
Younger than 6 months 158 (18%) 148 (17%)
Sex
Female 428 (48%) 447 (50%)
Male 463 (52%) 440 (50%)
Mother is primary caretaker 838 (94%) 823 (93%)
Caretaker completed primary 
education (n/total N)*
359/573 (63%) 347/577 (60%)
Currently breastfeeding 551 (62%) 541 (61%)
Received pneumococal conjugate 
vaccine†
524 (59%) 504 (57%)
Urban site 680 (76%) 676 (76%)
Nutritional oedema 149 (17%) 151 (17%)
MUAC (cm) 10·6 (1·09) 10·6 (1·05)
MUAC-for-age Z score ‡ –3·83 (1·05) –3·81 (0·99)
Weight-for-length Z score§ –3·35 (1·26) –3·32 (1·27)
Weight-for-age Z score§ –4·01 (1·12) –3·96 (1·09)
Length-for-age Z score –2·91 (1·67) –2·82 (1·64)
Head circumference-for-age Z 
score*
–1·82 (1·47) –1·73 (1·40)
Haemoglobin (g/L) 98·0 (21·4) 98·0 (22·4)
Clinical signs of rickets 129 (14%) 118 (13%)
Ocular signs of vitamin A deﬁ ciency 3 (<1%) 1 (<1%)
Cerebral palsy 34 (4%) 32 (4%)
Known tuberculosis at enrolment 31 (3%) 36 (4%)
Index admission for pneumonia 484 (54%) 474 (53%)
Index admission for diarrhoea 506 (57%) 515 (58%)
Treated for shock before enrolment 84 (9%) 100 (11%)
Impaired consciousness before 
enrolment
57 (6%) 56 (6%)
Days from admission to enrolment 6 (4–8) 6 (4–8)
Data are median (IQR), n (%), or mean (SD). MUAC=mid-upper-arm circumference. 
*Data obtained from April, 2011. †Received at least one dose of pneumococcal 
conjugate vaccine at enrolment. ‡Excludes infants younger than 3 months, because 
no WHO (2006) reference exists for younger than this age. §Excludes children with 
kwashiorkor (oedematous malnutrition).
Table 1: Baseline characteristics of the intention-to-treat population 
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occurred during the index admission, 64 (25%) during a 
readmission to a study hospital, 29 (11%) in other 
hospitals, and 104 (40%) in the community (characteristics 
of children who died at diﬀ erent times are in the 
appendix). Mortality did not diﬀ er between the groups: 
122 (14%) of 887 children in the co-trimoxazole group 
died, compared with 135 (15%) of 891 children in the 
placebo group (unadjusted hazard ratio [HR] 0·90, 
95% CI 0·71–1·16, p=0·429; 16·0 vs 17·7 events 
per 100 CYO, diﬀ erence –1·7 events per 100 CYO, 95% CI 
–5·8 to 2·4; ﬁ gure 2). Results were similar for an analysis 
adjusted for age and site (adjusted HR 0·92, 95% CI 
0·72–1·17; p=0·482).
No evidence was apparent for diﬀ erences in mortality 
between intervention groups within prespeciﬁ ed fatal 
clinical syndromes, apart from the category of other 
infections comprising febrile illnesses other than severe 
pneumonia, diarrhoea, or sepsis (HR 0·58, 95% CI 
0·36–0·92; table 2, appendix).
There was no evidence for heterogeneity of eﬀ ect by age 
group, the presence of kwashiorkor, site, or time period 
(appendix). In the 6 months after stopping study 
medication there was a non-signiﬁ cant reduction in 
mortality in the group assigned to co-trimoxazole 
(HR 0·56, 95% CI 0·31–1·02) and weak evidence of 
hetero geneity of eﬀ ect between the two periods (p=0·078).
Mortality was strongly associated with age, ranging 
from 11·1 per 100 CYO (95% CI 7·19–17·30) in children 
aged 24 months or more, to 31·0 per 100 CYO (95% CI 
24·8–39·0) in infants younger than 6 months (p<0·0001 
for trend across age groups; appendix).
There were 616 non-fatal admissions to hospital and 
3266 non-fatal episodes of illness for which children 
were treated as outpatients. The incidence of readmission 
to hospital or death during follow-up was 57·1 per 100 CYO 
(95% CI 54·6–59·6). We noted no signiﬁ cant diﬀ erences 
in the overall rates of hospital admission or outpatient 
illness between intervention groups (table 3, appendix). 
The frequency of pneumonia episodes was similar 
between groups, but diarrhoea occurred more frequently 
in the group assigned to co-trimoxazole (table 3). Skin or 
soft tissue infections, culture-conﬁ rmed urinary tract 
infections, and conﬁ rmed malaria were less frequent in 
the group assigned to co-trimoxazole.
During the trial, of 450 blood cultures done, 17 (3·8%) 
were positive for likely pathogens (appendix). The overall 
incidence of detected bacteraemia was 1·13 per 100 CYO 
(95% CI 0·65–1·78) and the overall incidence of detected 
culture-positive urinary tract infection was 4·06 per 
100 CYO (95% CI 3·11–5·21). Almost all bacterial 
pathogens isolated from blood and urine cultures were 
non-susceptible to co-trimoxazole, without evidence of 
diﬀ erences between treatment groups.
In the ﬁ rst 6 months of the study (while participants 
received study medication), 63 suspected grade 3 or 4 
adverse events were recorded in 57 (3%) children: 31 (2%) 
in the co-trimoxazole group and 32 (2%) in the placebo 
group (incidence rate ratio 0·98, 95% CI 0·58–1·65). The 
most common adverse events of these grades were 
urticarial rash (grade 3, equally common in both groups), 
neutropenia (grade 4, more common in the co-
trimoxazole group), and anaemia (both grades equally 
common in both groups). Scheduled neutrophil counts 
at months 2 and 6 were lower in the co-trimoxazole 
group (appendix). One child in the placebo group had 
fatal toxic epidermal necrolysis with concurrent 
Pseudomonas aeruginosa bacteraemia.
For all anthropometric variables assessed, no individual 
timepoint comparison between intervention groups was 
signiﬁ cant (ﬁ gure 3). Mean MUAC, weight-for-height, 
weight-for-age, and head circumference-for-age increased 
during follow-up. Mean length-for-age decreased during 
Placebo 
(n=891)
Co-trimoxazole 
(n=887)
Hazard ratio 
(95% CI)
All-cause mortality 135 (15%) 122 (14%) 0·90 (0·71–1·16)
Death from a 
speciﬁ c syndrome*
Severe pneumonia 46 (34%) 49 (40%) 1·07 (0·70–1·60)
Diarrhoea 25 (19%) 27 (22%) 1·08 (0·63–1·87)
Clinically deﬁ ned 
sepsis
27 (20%) 30 (25%) 1·11 (0·66–1·87)
Other infections† 47 (35%) 27 (22%) 0·58 (0·36–0·92)‡
Non-infectious 
causes§
5 (4%) 5 (4%) 0·98 (0·29–3·44)
Unknown cause¶ 22 (16%) 21 (17%) 0·96 (0·53–1·74)
Data are n (%) for all-cause mortality and n (% of deaths) for speciﬁ c syndromes. 
*The total for individual causes is greater than the number of deaths because 
more than one cause of death was identiﬁ ed in some children. †Details are 
presented in the appendix. ‡p=0·02. §Comprises three severe anaemia, two 
aspiration, one heart disease, one hepatic failure, one poisoning in the 
community, one drowning, and one during status epilepticus in a child with 
known epilepsy. ¶Deaths in the community without suﬃ  cient information to 
determine cause.
Table 2: Mortality (primary outcome) 
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Figure 2: Cumulative hazard curves for time to death
Kaplan-Meier curves are shown for time to death until 365 days. The time at risk 
observed was 763·3 and 763·3 child-years in the co-trimoxazole group and 
placebo group, respectively, of which 395·3 and 398·7 child-years, respectively, 
were during the ﬁ rst 6 months while receiving the study drug. HR=hazard ratio.
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the ﬁ rst 2 months, indicating a faltering of linear growth, 
and returned to a value similar to that recorded at 
enrolment at 6 and 12 months (appendix).
After 12 months, 1209 (68%) of 1778 children enrolled 
were alive and in follow-up with a MUAC above the 
threshold for moderate acute malnutrition (≥12·5 cm). 
However, this outcome varied with age, ranging from 160 
(52%) of 306 infants younger than 6 months at enrolment 
to 154 (78%) of 197 children aged 24 months or more at 
enrolment, p<0·0001 (appendix).
Overall, 1008 (57%) of 1778 participants were born 
before 2011 and wouldn’t have received PCV as part 
of their infant immunisation schedule. Of the 
770 participants born after introduction of PCV, 630 (82%) 
had three doses, 116 (15%) had two doses, 85 (11%) had 
one dose, and 53 (7%) had none. After adjustment for 
age, we noted no diﬀ erences in mortality risk between 
children born before and after 2011: HR 1·03 (95% CI 
0·76–1·35). No evidence was apparent for modiﬁ cation of 
the eﬀ ect of co-trimoxazole on mortality by birth before or 
after the introduction of PCV (p=0·512), nor receipt of 
two or more doses in children born after its introduction 
(p=0·812).
Diarrhoea and severe pneumonia were the most 
common reasons for admission to hospital immediately 
before enrol ment, aﬀ ecting 1499 (84%) of 1778 participants: 
541 (30%) with diarrhoea only, 478 (27%) with severe 
pneumonia only, and 480 (27%) with both these 
conditions. After adjustment for age, there was evidence 
of modiﬁ cation of the eﬀ ect of co-trimoxazole on mortality 
by these reasons for admission (p=0·036; appendix).
Discussion
Among Kenyan children with complicated SAM (but 
without HIV), daily co-trimoxazole given for 6 months 
was well tolerated, but did not reduce mortality or 
improve growth. However, as expected, it did result in a 
lower incidence of malaria and some bacterial infections. 
The ﬁ ndings from our trial suggest that children with 
complicated SAM remain susceptible to severe infections 
and death after discharge from hospital despite provision 
of recom mended medical and nutritional care and 
enhanced follow-up, with a rate of readmissions to 
hospital or death of 57 per 100 CYO. Among infants aged 
2–11 months, mortality was 22 per 100 CYO, which 
markedly contrasts with the national mortality estimate, 
reported in the 2014 Kenya Demographic & Health Survey 
for the previous 5 years, of 1·7 per 100 CYO among 
infants aged 1–11 months.21
Findings from clinical trials of co-trimoxazole 
prophylaxis have clearly established beneﬁ t for admission 
to hospital and survival in HIV-infected children.14 
However, trials with children who have been exposed to 
HIV but who are not HIV infected, in malaria-endemic 
areas such as Malawi and Uganda, report protection 
from malaria with co-trimoxazole prophylaxis, but not 
from other infections, nor improvements in growth.22–24 
In South Africa, for breastfed children exposed to HIV 
but not HIV infected in a non-malaria-endemic area, 
co-trimoxazole did not aﬀ ect pneumonia occurrence, but 
diarrhoea increased by a third (results of borderline 
statistical signiﬁ cance).25
During our study, malaria transmission was low in 
the speciﬁ c locations that we recruited from on the 
Kenyan Coast, and either low or absent in Nairobi. 
However, co-trimoxazole prophylaxis was eﬀ ective in 
preventing malaria. Overall, diarrhoea episodes were 
more frequent in children allocated to co-trimoxazole. 
Thus, our results are compatible with those from 
previous trials in children who were exposed to HIV but 
were not HIV infected.
A key question is whether low bacterial susceptibility to 
co-trimoxazole in our study contributed to an absence of 
protective eﬀ ect on death and the syndromes most 
commonly associated with serious illness. If so, this 
result would be of concern for the use of co-trimoxazole 
prophylaxis in HIV-infected children. In developing 
countries, the eﬀ ect of co-trimoxazole appears to be 
against a range of common infections rather than 
speciﬁ cally against Pneumocystis jirovecii. Findings from 
trials in individuals with HIV show similar eﬃ  cacy of co-
trimoxazole prophylaxis in countries with high (>80% in 
South Africa, Uganda, and Zambia) and low (<33% in 
Côte d’Ivoire)20 prevalence of co-trimoxazole non-
susceptibility in invasive bacterial isolates in vitro, using 
criteria based on treating established infections at 
standard antimicrobial doses. Additionally, in settings 
similar to Kenya, such as Uganda and Zimbabwe, 
Placebo (n=891) Co-trimoxazole 
(n=887)
Incidence rate ratio 
(95% CI)
Non-fatal hospital admissions 320 296 0·93 (0·79–1·09)
Hospital admission or death 455 418 0·92 (0·80–1·05)
Outpatient treatment 1666 1600 0·96 (0·89–1·03)
Outpatient, hospital admission, or 
death
2441 2314 0·95 (0·90–1·00)
All pneumonia 682 633 0·93 (0·83–1·04)
Severe pneumonia 200 193 0·97 (0·79–1·18)
All diarrhoea 458 512 1·14 (1·02–1·28)*
Severe diarrhoea 100 125 1·25 (0·95–1·64)
Conﬁ rmed malaria† 42 25 0·60 (0·35–0·99)*
Skin or soft tissue infection 176 136 0·77 (0·61–0·97)*
Urine culture done for clinical 
indication
80 58 0·73 (0·51–1·03)
Positive urine culture† 41/80 (51·3%) 21/58 (36·2%) 0·51 (0·29–0·89)*
Blood culture done for clinical 
indication
219 231 1·05 (0·87–1·28)
Positive blood culture† 8/219 (3·7%) 9/231 (3·9%) 1·13 (0·39–3·35)
Started treatment for tuberculosis 49 43 0·88 (0·57–1·35)
Suspected toxicity‡ 32 31 0·98 (0·58–1·65)
Data are the number of episodes or n (%) for laboratory tests. *p<0·05. †Details presented in the appendix. ‡ While 
receiving study medication (details in the appendix). 
Table 3: Secondary outcomes 
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co-trimoxazole prevented life-threatening infections in 
HIV-infected children.13
In our trial, we showed that, although the bacteria 
isolated from blood or urine were largely non-susceptible 
to co-trimoxazole, the drug did prevent two conditions 
that are almost always bacterial: urinary tract infection, 
for which antimicrobial concentrations are higher than 
in plasma, mainly caused by non-susceptible Entero-
bacteriaceae; and skin and soft tissue infections that were 
likely to have been caused by Staphylococcus aureus and 
group A streptococci. Considered together, the ﬁ ndings 
from trials on children with HIV, on children exposed to 
HIV but not HIV infected, and our trial suggest that the 
absence of eﬃ  cacy in our trial compared with those of 
children with HIV is likely to have been due to 
fundamental diﬀ erences in the immunopathology of 
mal nutrition and HIV infection, their associated 
infections, and their interaction with antimicrobials.
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Figure 3: Anthropometry during follow-up
Data are means; error bars indicate 95% CI. No individual timepoint comparisons between randomised groups were signiﬁ cant (appendix). MUAC=mid-upper-arm 
circumference.
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Few positive blood cultures were noted during our trial, 
despite high numbers of death and readmission, active 
screening for invasive bacterial disease, and a high 
prevalence of antimicrobial resistance. The population-
based incidence of bacteraemia was not markedly greater 
than that previously estimated within the general 
community of this age group on the Kenyan coast.26 
Although our trial and previous studies might have 
underestimated bacteraemia because of previous 
antibiotic use and non-presentation to hospital,11 our 
results raise the possibility that a substantial proportion 
of serious infections might not have been bacterial. 
Although detected invasive bacterial infection is generally 
associated with mortality, it typically accounts for few 
deaths in similar settings, especially after the introduction 
of conjugate vaccines against previously major causes of 
pneumonia and sepsis.27–29
We chose to investigate the eﬃ  cacy of co-trimoxazole 
because of its well documented eﬀ ect on mortality in 
children with HIV who present with infectious 
syndromes that are broadly similar to those noted in 
children with SAM. Among children with SAM, we 
noted two main reasons for initial admission: diarrhoea 
and pneumonia. In an exploratory analysis, we identiﬁ ed 
evidence that suggested that the reason for admission 
modiﬁ ed the eﬀ ect of co-trimoxazole on mortality. This 
ﬁ nding raises a hypothesis that SAM with diarrhoea 
might represent a phenotype amenable to antimicrobial 
prophylaxis targeting pathogens and commensal 
microbes, intestinal barrier function, and immune 
homoeostasis that could be tested in further trials.
Interest arose in the prophylactic use of azithromycin 
in children after a large, cluster-randomised clinical 
trial of mass administration in the general population 
for trachoma control in Ethiopia.30 In that trial, 
childhood mortality was 49% lower in the intervention 
groups, although the precise mechanism was unknown. 
In other contexts, azithromycin might prevent malaria, 
intestinal infections, and infections of the lower-
respiratory tract in children.31–33 Azithromycin, like 
co-trimoxazole, has some non-speciﬁ c anti-inﬂ am-
matory eﬀ ects and has a good safety proﬁ le. Up to now, 
no trials with high-mortality risk groups such as SAM 
have been done and azithromycin might be worth 
testing in these groups. Furthermore, in a prespeciﬁ ed 
analysis, we observed weak evidence suggesting a 
protective eﬀ ect after the 6-month period of allocation 
to co-trimoxazole. In a trial with children with un-
complicated SAM in Malawi,2 diﬀ erential mortality was 
noted after the period of antimicrobial administration 
between groups receiving amoxicillin, cefdinir, or 
placebo. However, no deaths occurring during the 
7 days of treatment in any of the randomised groups. 
Thus, a shorter period of prophylaxis or longer follow-
up might have altered the results of our trial.
There was a high prevalence of severe stunting among 
participants (69%), as reported previously in SAM.8 
Stunting was not reversed by therapeutic feeding and 
medical care during the trial. Thus, although children 
were recruited in hospital with criteria for SAM, 
indicators of chronic poor health were usually also 
present. Underlying factors probably included speciﬁ c 
nutritional deﬁ ciencies not adequately corrected by 
therapeutic and supplementary feeding strategies; 
intestinal inﬂ ammation and dysbiosis;34 a high burden of 
exposure to new infections; and social disadvantage and 
other factors associated with poverty.
Infants younger than 6 months had an especially high 
mortality (31 per 100 CYO) and poor long-term outcome—
only around half this age group had adequate MUAC 
(≥12·5 cm) after 12 months. Until 2011, SAM was assumed 
to be uncommon in infants younger than 6 months35 or 
simply a sequela of low birthweight not requiring speciﬁ c 
intervention strategies. Consequently, infants younger 
than 6 months are usually excluded from anthropometric 
screening for SAM in hospitals, in primary care, and in 
community nutritional surveys. Diagnostic cutoﬀ s for 
MUAC have not been internationally agreed. However, in 
this trial, infants younger than 6 months, recruited using 
MUAC values, comprised 17% of the participants and 
29% of the deaths. An update of WHO guidelines includes 
treatment recommendations for this age group, but 
evidence for their eﬃ  cacy is needed.4
Some limitations of our trial were that we were unable 
to identify whether prescribed therapeutic and sup-
plementary feeding met individual children’s nutritional 
requirements, or to accurately monitor compliance with 
feeding recommendations at home. We used routine 
diagnostic microbiology to diagnose infections, rather 
than enhanced molecular methods that might have 
improved the diagnosis of those that might have been 
inﬂ uenced by co-trimoxazole, including tuberculosis.
Despite an overall global reduction in child mortality, 
complicated SAM remains common in much of the 
developing world and is associated with high levels of 
short-term and long-term mortality. Tackling SAM will 
require better understanding of the causes of infections, 
determinants of susceptibility to infections, speciﬁ c 
nutritional and metabolic disturbances in relation to 
therapeutic and supplementary feeding strategies, and 
the parts played by social and environmental factors.
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